Zobrazeno 1 - 10
of 46
pro vyhledávání: '"M. Sh. Shamkhalova"'
Autor:
I. S. Maganeva, A. K. Eremkina, A. P. Miliutina, S. A. Martynov, A. S. Severina, R. H. Salimkhanov, M. I. Evloeva, M. Sh. Shamkhalova, M. V. Shestakova, N. G. Mokrysheva
Publikováno v:
Сахарный диабет, Vol 25, Iss 6, Pp 512-522 (2023)
BACKGROUND: In patients with end-stage CKD, receiving renal replacement therapy (RRT) with programmed hemodialysis (HD), the severity of complications is associated with metabolic disturbances: accumulation of uremic toxins, nephrogenic anemia, secon
Externí odkaz:
https://doaj.org/article/ab043f3f660e4dc087ac88de9c66acc9
Autor:
V. T. Ivashkin, M. V. Maevskaya, M. S. Zharkova, Yu. V. Kotovskaya, O. N. Tkacheva, E. A. Troshina, M. V. Shestakova, I. V. Maev, V. V. Breder, N. I. Gheivandova, V. L. Doshchitsin, E. N. Dudinskaya, E. V. Ershova, Kh. B. Kodzoeva, K. A. Komshilova, N. V. Korochanskaya, A. Yu. Mayorov, E. E. Mishina, M. Yu. Nadinskaya, I. G. Nikitin, N. V. Pogosova, A. I. Tarzimanova, M. Sh. Shamkhalova
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 32, Iss 4, Pp 104-140 (2022)
Aim: present clinical guidelines, aimed at general practitioners, gastroenterologists, cardiologists, endocrinologists, comprise up-to-date methods of diagnosis and treatment of non-alcoholic fatty liver disease.Key points. Nonalcoholic fatty liver d
Externí odkaz:
https://doaj.org/article/dd8d46c28c8d40eaa988a9d566abc2f4
Autor:
M. Sh. Shamkhalova, M. V. Shestakova
Publikováno v:
Сахарный диабет, Vol 25, Iss 3, Pp 204-214 (2022)
INTRODUCTION. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are the treatment options with comprehensive action on different aspects of type 2 diabetes. Due to its peptide nature GLP-1 RAs, until recent time the delivery of these agents into p
Externí odkaz:
https://doaj.org/article/f527795ab67d4ef7b3b81ab54da1c99c
Autor:
R. Kh. Salimkhanov, M. I. Yevloyeva, A. S. Severina, M. Sh. Shamkhalova, N. P. Trubitsyna, Y. G. Moysyuk
Publikováno v:
Сахарный диабет, Vol 25, Iss 2, Pp 192-198 (2022)
At the present time, a simultaneous pancreas-kidney transplantation (SPKT) is an effective method of treatment for patients on renal replacement therapy by hemodialysis program in the outcome of the terminal stage of diabetic nephropathy. This method
Externí odkaz:
https://doaj.org/article/aec8ef9e379243d49b5311a1d0fdbf7d
Publikováno v:
Сахарный диабет, Vol 24, Iss 3, Pp 273-281 (2021)
Oral semaglutide is the first-in-class glucagon-like peptide-1 receptor agonist available in the form of pills administered per os. PIONEER — the clinical trial program assessing the efficacy and safety of oral semaglutide — demonstrated the dose
Externí odkaz:
https://doaj.org/article/99990b0602704bc38e17bcf6dfbda6fa
Autor:
S. A. Martynov, M. Sh. Shamkhalova
Publikováno v:
Медицинский совет, Vol 0, Iss 16, Pp 78-85 (2019)
Hyperphosphatemia in renal pathology is a key factor for developing mineral and bone disorders. It can develop even in the early stages of renal function decline and predict the formation of vascular calcification and an increased risk for developing
Externí odkaz:
https://doaj.org/article/20089e150aff4a1eb623b05552bfdefd
Autor:
I. I. Dedov, M. V. Shestakova, A. Yu. Mayorov, T. V. Nikonova, G. R. Galstyan, M. Sh. Shamkhalova, O. K. Vikulova, V. Yu. Kalashnikov, N. G. Mokrysheva
Publikováno v:
Сахарный диабет, Vol 24, Iss 1, Pp 74-75 (2021)
Externí odkaz:
https://doaj.org/article/3764346bf4cf47a88b094aff76079ded
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 9, Iss 2, Pp 152-157 (2015)
Aim. To evaluate the effect of parathyroidectomy and cinacalcet on anemia, lipid profile and blood pressure (BP) in uremic hyperparathyroidism.Material and methods. Uremic patients (n=39) treated with hemodialysis and having secondary hyperparathyroi
Externí odkaz:
https://doaj.org/article/e00d86bc59fd4fb0a305dd039576982e
Autor:
V. C. Moiseev, N. A. Mukhin, A. V. Smirnov, J. D. Kobalava, I. N. Bobkova, S. V. Villevalde, M. A. Yefremovtseva, L. V. Kozlovskaya, M. Yu. Shvetsov, M. V. Shestakova, G. P. Arutyunov, S. A. Boytsov, A. S. Galyavich, Y. I. Greenstein, V. A. Dobronravov, O. M. Drapkina, V. M. Ermolenko, Yu. A. Karpov, I. G. Kayukov, J. V. Kotovsky, V. V. Kukharchuk, A. I. Martynov, T. E. Morozova, R. G. Oganov, V. I. Podzolkov, L. Ya. Rozhinskaya, S. N. Tereshchenko, V. V. Fomin, V. N. Khirmanov, I. E. Chazova, M. Sh. Shamkhalova, E. M. Shilov, E. V. Shlyakhto, A. M. Shutov
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 8, Pp 7-37 (2014)
Externí odkaz:
https://doaj.org/article/d1bd210a3de646beb2e4bd0da7c2ac53
Autor:
I. S. Maganeva, A. K. Eremkina, A. P. Miliutina, S. A. Martynov, A. S. Severina, R. H. Salimkhanov, M. I. Evloeva, M. Sh. Shamkhalova, M. V. Shestakova, N. G. Mokrysheva
Publikováno v:
Diabetes mellitus. 25:512-522
BACKGROUND: In patients with end-stage CKD, receiving renal replacement therapy (RRT) with programmed hemodialysis (HD), the severity of complications is associated with metabolic disturbances: accumulation of uremic toxins, nephrogenic anemia, secon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ba095a0cc1ba8141747397f32dd6ba8
https://doi.org/10.14341/dm12958
https://doi.org/10.14341/dm12958